These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy? Steele P; Strange G; Wlodarczyk J; Dalton B; Stewart S; Gabbay E; Keogh A BMC Cardiovasc Disord; 2010 Feb; 10():9. PubMed ID: 20170553 [TBL] [Abstract][Full Text] [Related]
4. [Pulmonary hypertension in human immunodeficiency virus-infected patients: the role of antiretroviral therapy]. Olalla J; Urdiales D; Pombo M; del Arco A; de la Torre J; Prada JL Med Clin (Barc); 2014 Mar; 142(6):248-52. PubMed ID: 23490486 [TBL] [Abstract][Full Text] [Related]
5. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. McLaughlin VV Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005 [TBL] [Abstract][Full Text] [Related]
6. Bosentan in pediatric patients with pulmonary arterial hypertension. Beghetti M Curr Vasc Pharmacol; 2009 Apr; 7(2):225-33. PubMed ID: 19356006 [TBL] [Abstract][Full Text] [Related]
7. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849 [TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974 [TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III. Stevenson MD; Macdonald FC; Langley J; Hunsche E; Akehurst R Value Health; 2009; 12(8):1100-5. PubMed ID: 19558373 [TBL] [Abstract][Full Text] [Related]
10. HIV-associated pulmonary arterial hypertension: from bedside to the future. Correale M; Palmiotti GA; Lo Storto MM; Montrone D; Foschino Barbaro MP; Di Biase M; Lacedonia D Eur J Clin Invest; 2015 May; 45(5):515-28. PubMed ID: 25715739 [TBL] [Abstract][Full Text] [Related]
11. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355 [TBL] [Abstract][Full Text] [Related]
13. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Humbert M; Barst RJ; Robbins IM; Channick RN; Galiè N; Boonstra A; Rubin LJ; Horn EM; Manes A; Simonneau G Eur Respir J; 2004 Sep; 24(3):353-9. PubMed ID: 15358690 [TBL] [Abstract][Full Text] [Related]
14. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. Degano B; Guillaume M; Savale L; Montani D; Jaïs X; Yaici A; Le Pavec J; Humbert M; Simonneau G; Sitbon O AIDS; 2010 Jan; 24(1):67-75. PubMed ID: 19770696 [TBL] [Abstract][Full Text] [Related]
15. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Sitbon O; Gressin V; Speich R; Macdonald PS; Opravil M; Cooper DA; Fourme T; Humbert M; Delfraissy JF; Simonneau G Am J Respir Crit Care Med; 2004 Dec; 170(11):1212-7. PubMed ID: 15317666 [TBL] [Abstract][Full Text] [Related]
16. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. Opravil M; Sereni D AIDS; 2008 Sep; 22 Suppl 3():S35-40. PubMed ID: 18845920 [TBL] [Abstract][Full Text] [Related]
17. Treatment and outcome of pulmonary arterial hypertension in HIV-infected patients: a review of the literature. Cicalini S; Chinello P; Grilli E; Petrosillo N Curr HIV Res; 2009 Nov; 7(6):589-96. PubMed ID: 19929793 [TBL] [Abstract][Full Text] [Related]
18. [HIV-related pulmonary arterial hypertension]. Savale L; Lador F; Jais X; Montani D; Simonneau G; Humbert M; Sitbon O Rev Mal Respir; 2012 Apr; 29(4):491-500. PubMed ID: 22542407 [TBL] [Abstract][Full Text] [Related]
19. Effects of long-term bosentan in children with pulmonary arterial hypertension. Rosenzweig EB; Ivy DD; Widlitz A; Doran A; Claussen LR; Yung D; Abman SH; Morganti A; Nguyen N; Barst RJ J Am Coll Cardiol; 2005 Aug; 46(4):697-704. PubMed ID: 16098438 [TBL] [Abstract][Full Text] [Related]
20. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. Benza RL; Rayburn BK; Tallaj JA; Pamboukian SV; Bourge RC Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]